Isomorphic aims to scale new predictive AI model with $2.1B: Venture Report

One of the largest venture rounds in biotech history will allow Isomorphic to apply its predictive models to the drug discovery process at greater scale, including its use of a new product introduced in February.

Isomorphic Labs Ltd., the London-headquartered spinout of the Google DeepMind unit of Alphabet Inc. (NASDAQ:GOOG), said this week that a syndicate led by Thrive Capital is supplying $2.1 billion in series B funding, with new and existing investors participating. The round trails in size only the $3 billion round for Altos Labs Inc. in 2022 among venture rounds for biotechs, according to BioCentury’s BCIQ database...